Associações entre o Risco Cardiovascular e as Taxas de Incidência de Eventos Cardiovasculares Maiores e Malignidades em Pacientes com Artrite Psoriásica Recebendo Tofacitinib

Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.

These results confirm the importance of assessing CV risk and adequate prevention in patients with PsA and PsO and suggest enhanced cancer monitoring in patients with significant 10-year ASCVD risk.